Verici Dx (LSE:VRCI) 1-Year Share Buyback Ratio : -42.40% (As of Jun. 2024 )

View and export this data going back to 2020. Start your Free Trial

What is Verici Dx 1-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Verici Dx's current 1-Year Share Buyback Ratio was -42.40%.

LSE:VRCI's 1-Year Share Buyback Ratio is ranked worse than
80.75% of 161 companies
in the Medical Diagnostics & Research industry
Industry Median: -1.9 vs LSE:VRCI: -42.40

Competitive Comparison of Verici Dx's 1-Year Share Buyback Ratio

For the Diagnostics & Research subindustry, Verici Dx's 1-Year Share Buyback Ratio, along with its competitors' market caps and 1-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Verici Dx's 1-Year Share Buyback Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's 1-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Verici Dx's 1-Year Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

Verici Dx 1-Year Share Buyback Ratio Calculation

Verici Dx's 1-Year Share Buyback Ratio for the quarter that ended in Jun. 2024 is calculated as

1-Year Share Buyback Ratio	=	(Shares Outstanding (EOP) (Jun. 2023 )	-	Shares Outstanding (EOP) (Jun. 2024 ))	/	Shares Outstanding (EOP) (Jun. 2023 )
	=	(170.319	-	242.541)	/	170.319
	=	-42.4%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Verici Dx (LSE:VRCI) 1-Year Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Verici Dx 1-Year Share Buyback Ratio Related Terms

Verici Dx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (LSE:VRCI) » Definitions » 1-Year Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

63V:Germany

Address

19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ

Website

https://www.vericidx.com

Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies that will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx Headlines

No Headlines